Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO Oxford, UK – 18 ...

Oxford BioMedica has signed a deal worth up to $100m with Novartis to supply modified viruses used to generate its CAR-T therapies. The deal represents a major financial boost for the UK biotech ...

Gene and cell therapy specialist Oxford Biomedica has signed a one-year agreement with AstraZeneca to manufacture the potential COVID-19 vaccine in development in partnership with Oxford ...

Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, "OXB" or “the Company”), a ...

Oxford Biomedica has rebranded as OXB to reinforces the firm’s transformation into a global pure-play cell and gene therapy ...

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based ...

Invenra Inc. is pleased to announce the addition of three distinguished professionals to its Board of Directors: Saira ...

Researchers identified five factors that predict response to immunotherapy, advancing personalized cancer treatment. This ...

Researchers have found evidence that low oxygen levels in tumors could actually enhance some of the body's immune responses against cancer, in contrast with the general paradigm that hypoxia ...

Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, "OXB" or “the Company”), a quality and innovation-led cell and gene therapy CDMO, announces that ...

Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Oxford, UK – 2 September 2024: Oxford Biomedica plc ...